Medicover Future Growth
Future criteria checks 5/6
Medicover is forecast to grow earnings and revenue by 24.1% and 10.8% per annum respectively. EPS is expected to grow by 20.7% per annum. Return on equity is forecast to be 22% in 3 years.
Key information
24.1%
Earnings growth rate
20.74%
EPS growth rate
| Healthcare earnings growth | 18.1% |
| Revenue growth rate | 10.8% |
| Future return on equity | 22.01% |
| Analyst coverage | Good |
| Last updated | 05 May 2026 |
Recent future growth updates
Analysis Article • May 02
Earnings Beat: Medicover AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Investors in Medicover AB (publ) ( STO:MCOV B ) had a good week, as its shares rose 5.4% to close at kr208 following...Analysis Article • Jul 27
Medicover AB (publ) Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next
Investors in Medicover AB (publ) ( STO:MCOV B ) had a good week, as its shares rose 9.4% to close at kr286 following...Recent updates
Narrative Update • Jun 02
MCOV B: Lower Discount Rate Will Support Future Upside Potential
Analysts have nudged their Medicover price target slightly higher to around SEK257 per share, reflecting minor adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions in their models. What's in the News No recent company specific news items, periodical coverage or key developments were provided for Medicover in the supplied sources.Narrative Update • May 16
MCOV B: Dividend Uplift And 2028 Revenue Ambition Will Support Future Upside
Analysts have nudged their Medicover price target slightly lower to SEK256.96 from SEK257.29, reflecting small adjustments to the discount rate, revenue growth, profit margin and future P/E assumptions. Valuation Changes Fair Value: SEK257.29 to SEK256.96, representing a very small downward adjustment in the modelled estimate.Analysis Article • May 02
Earnings Beat: Medicover AB (publ) Just Beat Analyst Forecasts, And Analysts Have Been Updating Their Models
Investors in Medicover AB (publ) ( STO:MCOV B ) had a good week, as its shares rose 5.4% to close at kr208 following...
Narrative Update • Apr 21
MCOV B: Dividend Plans And 2028 Revenue Aims Will Shape Fair Outlook
Analysts have made a small downward adjustment to Medicover's fair value estimate, moving the target from SEK 227.29 to SEK 225.02. The revision reflects updated views on revenue growth, profit margins and future P/E assumptions.Narrative Update • Apr 07
MCOV B: Dividend Growth And 2028 Revenue Ambitions Will Support Upside
Analysts have nudged their Medicover price target higher to SEK227.29 from SEK225.05, citing updated assumptions that reflect a slightly higher discount rate, along with revised expectations for revenue growth, profit margins and future P/E. What's in the News The board proposes a dividend of €0.20 per share for the 2025 financial year, compared with €0.15 previously, subject to approval at the annual general meeting on 29 April 2026 (Key Developments).
Narrative Update • Mar 23
MCOV B: Dividend Policy And 2028 Revenue Ambition Will Drive Future Upside
Analysts have trimmed their Medicover price target from SEK 325 to SEK 307 as updates to fair value, discount rate, revenue growth, profit margin assumptions and expected future P/E filter through their models. What's in the News The board proposes a dividend of SEK 0.20 per share for the 2025 financial year, up from SEK 0.15, subject to approval at the annual general meeting on 29 April 2026 (Key Developments).Narrative Update • Mar 09
MCOV B: Dividend Uplift And 2028 Revenue Ambition Will Support Future Upside
Analysts have kept their price target for Medicover broadly unchanged at around SEK 257, reflecting stable assumptions on the discount rate, revenue growth, profit margin and future P/E multiples. What's in the News The board of Medicover AB proposes a dividend of SEK 0.20 per share for the financial year 2025, compared with SEK 0.15 previously, subject to approval at the annual general meeting on 29 April 2026 (Key Developments).Narrative Update • Feb 23
MCOV B: Higher Margin Outlook And Dividend Plans Will Support Future Upside
Analysts have nudged their Medicover price target higher to SEK257.29 from SEK252.68, citing updated assumptions that pair slightly lower revenue growth expectations with a modestly stronger profit margin and a revised future P/E of 24.46x. What's in the News Board proposes a dividend of €0.20 per share for the 2025 financial year, compared with €0.15 previously, subject to approval at the annual general meeting on 29 April 2026 (Key Developments).Analysis Article • Feb 11
With Medicover AB (publ) (STO:MCOV B) It Looks Like You'll Get What You Pay For
Medicover AB (publ)'s ( STO:MCOV B ) price-to-earnings (or "P/E") ratio of 46.4x might make it look like a strong sell...Narrative Update • Feb 09
MCOV B: Higher Revenue And Margin Assumptions Will Support Stronger Future Earnings Multiples
Analysts have trimmed their price target for Medicover from €267.22 to €252.68, citing updated assumptions around discount rates, revenue growth, profit margins, and a lower future P/E multiple as the key drivers of the revision. Valuation Changes Fair Value: Trimmed from €267.22 to €252.68, a reduction of around €14.54 per share.Narrative Update • Jan 26
MCOV B: Refined Assumptions Will Support Steady Long Term Prospects
Analysts have trimmed their price target for Medicover from €230.73 to €225.05 as updated assumptions for revenue growth, profit margins and future P/E lead to a slightly lower assessed fair value. Valuation Changes Fair Value: Trimmed from €230.73 to €225.05, a small reduction in the assessed price level.Narrative Update • Jan 11
MCOV B: MRD Study Progress Will Support Balanced Long Term Prospects
Analysts have lifted their price target on Medicover to €230.73 per share, reflecting updated assumptions that combine a higher revenue growth outlook of 13.50% with a slightly lower profit margin of 4.09% and a modestly higher future P/E of 27.52x. What's in the News Additional results from the ongoing DART clinical study using Medicover Genetics' hybrid capture based, tumour agnostic MRD assay were presented at the European Society for Medical Oncology Congress in Berlin on 18 October 2025.Narrative Update • Dec 26
MCOV B: MRD Study Progress Will Support Steady Long Term Outlook
Analysts have raised their price target on Medicover to SEK 230.73 per share, reflecting modestly stronger expectations for long term revenue growth and profit margins despite an essentially unchanged valuation framework. What's in the News Medicover reported additional data from the ongoing DART phase II clinical study at Oslo University Hospital, using Medicover Genetics' hybrid capture based, tumour agnostic MRD assay in unresectable stage III NSCLC patients (Key Developments).Analysis Article • Dec 16
We Think Medicover (STO:MCOV B) Can Stay On Top Of Its Debt
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Narrative Update • Dec 12
MCOV B Expects MRD Assay Validation To Support Balanced Long Term Outlook
Analysts have raised their price target on Medicover from €219.05 to €230.73, citing slightly stronger expectations for revenue growth and profit margins that more than offset a modestly higher discount rate and a marginally lower assumed future P/E multiple. What's in the News Additional DART clinical study results from Oslo University Hospital further validate Medicover Genetics' ctDNA-based MRD assay as a strong predictor of disease progression in unresectable stage III NSCLC, supporting its path toward clinical validation and commercialisation (Key Developments) The updated DART data set, now including 640 plasma samples from 84 patients, shows that detectable ctDNA during and after durvalumab treatment following chemoradiotherapy is strongly associated with inferior progression free survival, underscoring the assay's prognostic value (Key Developments) Detection of ctDNA at six months after initiation of durvalumab and three months after its completion is linked to significantly poorer progression free survival, with ctDNA often indicating disease progression a median of 7.4 months before imaging.Analysis Article • Nov 30
What Does Medicover AB (publ)'s (STO:MCOV B) Share Price Indicate?
Medicover AB (publ) ( STO:MCOV B ), is not the largest company out there, but it saw significant share price movement...Analysis Article • Nov 13
The Strong Earnings Posted By Medicover (STO:MCOV B) Are A Good Indication Of The Strength Of The Business
Even though Medicover AB (publ)'s ( STO:MCOV B ) recent earnings release was robust, the market didn't seem to notice...Analysis Article • Sep 24
Medicover (STO:MCOV B) Might Have The Makings Of A Multi-Bagger
What are the early trends we should look for to identify a stock that could multiply in value over the long term...Analysis Article • Sep 01
Medicover AB (publ) (STO:MCOV B) Not Lagging Industry On Growth Or Pricing
Medicover AB (publ)'s ( STO:MCOV B ) price-to-sales (or "P/S") ratio of 1.6x may not look like an appealing investment...Analysis Article • Jul 27
Medicover AB (publ) Just Beat EPS By 18%: Here's What Analysts Think Will Happen Next
Investors in Medicover AB (publ) ( STO:MCOV B ) had a good week, as its shares rose 9.4% to close at kr286 following...Analysis Article • Jul 22
Medicover (STO:MCOV B) Seems To Use Debt Quite Sensibly
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' It's only natural to consider a company's...Analysis Article • May 09
Medicover's (STO:MCOV B) Earnings May Just Be The Starting Point
Medicover AB (publ)'s ( STO:MCOV B ) strong earnings report was rewarded with a positive stock price move. We have done...Analysis Article • Apr 28
Medicover AB (publ)'s (STO:MCOV B) Intrinsic Value Is Potentially 41% Above Its Share Price
Key Insights The projected fair value for Medicover is kr297 based on 2 Stage Free Cash Flow to Equity Medicover's...Analysis Article • Apr 14
Investors Interested In Medicover AB (publ)'s (STO:MCOV B) Revenues
When you see that almost half of the companies in the Healthcare industry in Sweden have price-to-sales ratios (or...Analysis Article • Mar 21
Medicover (STO:MCOV B) Might Be Having Difficulty Using Its Capital Effectively
What are the early trends we should look for to identify a stock that could multiply in value over the long term? One...
New Narrative • Feb 09
New Investments In India's And Romania's Healthcare Services Will Expand Future Global Reach
Strong cash generation supports debt reduction and further investments, boosting future earnings growth positively.Analysis Article • Dec 12
Medicover AB (publ)'s (STO:MCOV B) Popularity With Investors Is Clear
When you see that almost half of the companies in the Healthcare industry in Sweden have price-to-sales ratios (or...Analysis Article • Nov 07
The Strong Earnings Posted By Medicover (STO:MCOV B) Are A Good Indication Of The Strength Of The Business
Medicover AB (publ) ( STO:MCOV B ) just reported healthy earnings but the stock price didn't move much. Investors are...Analysis Article • Oct 24
Here's What To Make Of Medicover's (STO:MCOV B) Decelerating Rates Of Return
If we want to find a stock that could multiply over the long term, what are the underlying trends we should look for...Analysis Article • Apr 22
Investors Appear Satisfied With Medicover AB (publ)'s (STO:MCOV B) Prospects
When close to half the companies in the Healthcare industry in Sweden have price-to-sales ratios (or "P/S") below 0.4x...Analysis Article • Apr 04
Additional Considerations Required While Assessing Medicover's (STO:MCOV B) Strong Earnings
Medicover AB (publ) ( STO:MCOV B ) announced strong profits, but the stock was stagnant. Our analysis suggests that...Analysis Article • Mar 05
Medicover (STO:MCOV B) Has A Pretty Healthy Balance Sheet
Some say volatility, rather than debt, is the best way to think about risk as an investor, but Warren Buffett famously...Analysis Article • Feb 11
Medicover AB (publ)'s (STO:MCOV B) Intrinsic Value Is Potentially 31% Above Its Share Price
Key Insights Medicover's estimated fair value is kr204 based on 2 Stage Free Cash Flow to Equity Medicover's kr156...Analysis Article • Dec 20
Returns On Capital At Medicover (STO:MCOV B) Paint A Concerning Picture
What trends should we look for it we want to identify stocks that can multiply in value over the long term? Firstly...Analysis Article • Dec 02
Does Medicover (STO:MCOV B) Have A Healthy Balance Sheet?
Warren Buffett famously said, 'Volatility is far from synonymous with risk.' So it might be obvious that you need to...Earnings and Revenue Growth Forecasts
| Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
|---|---|---|---|---|---|
| 12/31/2028 | 3,323 | 176 | 245 | 413 | 6 |
| 12/31/2027 | 2,986 | 140 | 202 | 354 | 6 |
| 12/31/2026 | 2,663 | 102 | 167 | 264 | 6 |
| 3/31/2026 | 2,424 | 80 | 173 | 329 | N/A |
| 12/31/2025 | 2,378 | 78 | 186 | 344 | N/A |
| 9/30/2025 | 2,322 | 67 | 166 | 308 | N/A |
| 6/30/2025 | 2,258 | 43 | 157 | 281 | N/A |
| 3/31/2025 | 2,171 | 31 | 148 | 271 | N/A |
| 12/31/2024 | 2,092 | 17 | 140 | 262 | N/A |
| 9/30/2024 | 1,998 | 20 | 122 | 240 | N/A |
| 6/30/2024 | 1,911 | 23 | 116 | 225 | N/A |
| 3/31/2024 | 1,826 | 22 | 113 | 222 | N/A |
| 12/31/2023 | 1,746 | 18 | 95 | 205 | N/A |
| 9/30/2023 | 1,682 | 8 | 90 | 205 | N/A |
| 6/30/2023 | 1,610 | 5 | 75 | 202 | N/A |
| 3/31/2023 | 1,548 | 1 | 43 | 186 | N/A |
| 12/31/2022 | 1,510 | 12 | 30 | 170 | N/A |
| 9/30/2022 | 1,489 | 37 | 45 | 182 | N/A |
| 6/30/2022 | 1,455 | 59 | 67 | 195 | N/A |
| 3/31/2022 | 1,442 | 88 | 95 | 205 | N/A |
| 12/31/2021 | 1,377 | 102 | 115 | 217 | N/A |
| 9/30/2021 | 1,299 | 93 | 105 | 202 | N/A |
| 6/30/2021 | 1,226 | 90 | 91 | 176 | N/A |
| 3/31/2021 | 1,076 | 52 | 104 | 176 | N/A |
| 12/31/2020 | 998 | 26 | 83 | 155 | N/A |
| 9/30/2020 | 930 | 14 | 75 | 141 | N/A |
| 6/30/2020 | 879 | 4 | 53 | 122 | N/A |
| 3/31/2020 | 884 | 16 | 31 | 100 | N/A |
| 12/31/2019 | 844 | 23 | N/A | 87 | N/A |
| 9/30/2019 | 796 | 19 | N/A | 79 | N/A |
| 6/30/2019 | 751 | 19 | N/A | 86 | N/A |
| 3/31/2019 | 709 | 20 | N/A | 85 | N/A |
| 12/31/2018 | 672 | 22 | N/A | 74 | N/A |
| 9/30/2018 | 643 | 28 | N/A | 75 | N/A |
| 6/30/2018 | 620 | 26 | N/A | 61 | N/A |
| 3/31/2018 | 600 | 23 | N/A | 55 | N/A |
| 12/31/2017 | 580 | 19 | N/A | 50 | N/A |
| 9/30/2017 | 560 | 10 | N/A | 40 | N/A |
| 6/30/2017 | 540 | 9 | N/A | 36 | N/A |
| 3/31/2017 | 522 | 6 | N/A | 31 | N/A |
| 12/31/2016 | 497 | 4 | N/A | 26 | N/A |
| 12/31/2015 | 416 | 8 | N/A | 29 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: MCOV B's forecast earnings growth (24.1% per year) is above the savings rate (2%).
Earnings vs Market: MCOV B's earnings (24.1% per year) are forecast to grow faster than the Swedish market (8.6% per year).
High Growth Earnings: MCOV B's earnings are expected to grow significantly over the next 3 years.
Revenue vs Market: MCOV B's revenue (10.8% per year) is forecast to grow faster than the Swedish market (-0.03% per year).
High Growth Revenue: MCOV B's revenue (10.8% per year) is forecast to grow slower than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: MCOV B's Return on Equity is forecast to be high in 3 years time (22%)
Discover growth companies
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/06/09 17:46 |
| End of Day Share Price | 2026/06/09 00:00 |
| Earnings | 2026/03/31 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Medicover AB (publ) is covered by 10 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| null null | ABG Sundal Collier |
| null null | ABG Sundal Collier Sponsored |
| Kristofer Liljeberg-Svensson | Carnegie Investment Bank AB |